


PHARMACEUTICAL 2018

MyoKardia Inc. Rank 66 of 349





PHARMACEUTICAL 2018



MyoKardia Inc. Rank 66 of 349

The relative strengths and weaknesses of MyoKardia Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MyoKardia Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 151% points. The greatest weakness of MyoKardia Inc. is the variable Revenues, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 49%, being 326% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	259,393
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	40,872
Liabilities, Non-Current	202
Other Assets	20,268
Other Compr. Net Income	-200
Other Expenses	0
Other Liabilities	0
Other Net Income	24,157
Property and Equipment	3,147
Research and Development	48,136
Revenues	0
Selling, General and Administrative Expense	21,973

Output Variable	Value in 1000 USD
Assets	282,808
Liabilities	41,074
Expenses	70,109
Stockholders Equity	241,734
Net Income	-45,952
Comprehensive Net Income	-46,052
Economic Capital Ratio	49%